GSK bets $3.3B on a buyout, jumping into a blockbuster showdown with Pfizer and Merck
Count GSK in for the pneumococcal vaccine race.
The British pharma is wagering $2.1 billion in cash — plus up to $1.2 billion in milestones — to buy out Affinivax and its 24-valent pneumococcal vaccine candidate, now in Phase II, as well as the technology that gave birth to the shot.
“The proposed acquisition further strengthens our vaccines R&D pipeline, provides access to a new, potentially disruptive technology, and broadens GSK’s existing scientific footprint in the Boston area,” said outgoing R&D chief Hal Barron, who’s leaving in August to run the cell rejuvenation startup Altos Labs.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,700+ biopharma pros reading Endpoints daily — and it's free.